Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer

Bone Marrow Transplantation

Volumn 19, Issue 4, 1997, Pages 331-336

  Tomas J F ^a,c   Perez Carrion R ^a   Escudero, A ^b   Lopez Lorenzo J L ^b   Lopez Pascual J ^b   Fernandez Ranada J M ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL RUBER INTERNACIONAL   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Autologous stem cell transplantation; High dose chemotherapy; High risk breast cancer

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; TAMOXIFEN; THIOTEPA;

ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER INVASION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOPOIESIS; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG EMBOLISM; LUNG HEMORRHAGE; METASTASIS; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION; STOMATITIS; TACHYCARDIA; TACHYPNEA; VOMITING; WEIGHT GAIN;

EID: 1842299856     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700658     Document Type: Article

References (34)

1. Peters WP. High-dose chemotherapy and autologous bone marrow support for breast cancer. In: DeVita VT, Hellman S, Rosenberg A (eds). Important Advances in Oncology. Lippincott: Philadelphia, 1991, pp 135-150.
2. Jones SE, Moon TE, Bonadonna G et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987; 10: 387-395.
3. Hryniuk WM, Levine MM, Levine M. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. Natl Cancer Inst Monogr 1986; 1: 87-94.
4. Bonadonna G, Valaussa P. Dose response effect of adjuvant chemotherapy in breast cancer. New Engl J Med 1981; 305: 10-15.
5. Hrynuik W. Average relative dose intensity and the impact on the design of future clinical trials. Semin Oncol 1987; 14: 65-74.
6. Goldhirsh A, Gelber RD. Understanding adjuvant chemotherapy for breast cancer. New Engl J Med 1994; 330: 1308-1309.
7. Skipper HE, Schabel FM Jr. Tumor stem cell heterogenity: implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 1984; 68: 43-61.
8. Frei E III, Cucchi C, Rosowsky A et al. Alkylating agent resistance: in vitro studies of human cell lines. Proc Natl Acad Sci USA 1985; 82: 2158-2162.
9. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
10. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
11. Slease RB, Benear JB, Selby GB et al. High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 1988; 6: 1314-1320.
12. Sobocinski KA, Horowitz MM, Rowlings PA et al. Bone marrow transplantation - 1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother 1994; 3: 95-102.
13. Peters WP, Fay JW, Holland JW et al. Autologous bone marrow transplantation in primary breast cancer: the American experience. Bone Marrow Transplant 1995; 15 (Suppl. 1): 254-259.
14. Vahdat L, Antman K. High-dose therapy for breast cancer. Blood Rev 1995; 9: 191-200.
15. Vaughan W. Autologous bone marrow transplantation in the treatment of breast cancer: clinical and technologic strategies. Semin Oncol 1993; 20 (Suppl. 6): 55-58.
16. Peters W, Ross M, Vrenderburgh JJ et al. High-dose alkylating agents and autologous bone marrow support (ABMS) for stage II/III breast cancer involving 10 or more axillary lymph nodes (Duke and CALGB 8782). Proc Am Soc Clin Oncol 1992; 11: 102 (Abstr. 59).
17. Antman K, Bearman S, Davidson N et al. High-dose therapy in breast cancer with autologous bone marrow support: current status. In: Gale RP, Champlin RE (eds). New Strategies in Bone Marrow Transplantation. Alan R Liss: New York, 1991. pp 423-426.
18. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for breast cancer. J Clin Oncol 1988; 6: 1811-1814.
19. Eder JP, Elias A, Shea TC et al. A phase I/II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-1245.
20. Tomás JF, Gómez-García de Soria V, López-Lorenzo JL et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Marrow Transplant 1996; 17: 979-984.
21. Alegre A, Lamana M, Arranz R et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91: 380-386.
22. Bearman SI,Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. McDonald GB, Sharma P, Matthews DE el al. Venocclusive disease of the liver after bone marrow trasnplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
25. Gruss E, Bernis C, Tomás JF et al. Acute renal failure in patients following bone marrow transplantation: Prevalence, risk factors and outcome. Am J Nephrol 1995; 15: 473-479.
26. van der Wall E, Nooijen WJ, Baars JW et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995; 71: 857-862.
27. Holland HK, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophasmide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-1164.
28. Ross M, Dukelow K, Kasprzak S et al. Outpatient bone marrow transplantation: two year update. Proc Am Soc Clin Oncol 1995; 14: 316 (Abstr. 930).
29. Miyahara TT, Dix SP, Devine SM et al. Evaluation of supportive care guidelines for monitoring breast cancer bone marrow transplant (BMT) in the outpatient setting. Blood 1995; 86 (Suppl. 1): 213a (Abstr. 838).
30. Robbins R, Linder J, Stahl MG et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989; 87: 511-516.
31. Chao NJ, Duncan SR, Long GD et al. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Ann Intern Med 1991; 114: 145-149.
32. Robbins R, Thomson AB, Rennard S et al. Association of neutrophils with diffuse aleveolar hemorrhage in autologous bone marrow transplantation. Clin Res 1988; 36: 373A (Abstr.).
33. Peters W, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
34. Peters W, Rogers MC. Variation in approval by insurance companies of coverage for autologous hone marrow transplantation for breast cancer. New Engl J Med 1994; 330: 473-477.